Literature DB >> 21931032

Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.

Ignace Vergote1, Claes G Tropé, Frédéric Amant, Tom Ehlen, Nick S Reed, Antonio Casado.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21931032     DOI： 10.1200/JCO.2011.36.9785

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  23 in total

1.  Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.

Authors:  Seiya Sato; Hiroaki Itamochi
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).

Authors:  Jennifer M Scalici; Sanja Arapovic; Erin J Saks; Kristen A Atkins; Gina Petroni; Linda R Duska; Jill K Slack-Davis
Journal:  Cancer       Date:  2016-11-07       Impact factor: 6.860

3.  Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Authors:  Sonali Patankar; William M Burke; June Y Hou; Ana I Tergas; Yongmei Huang; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-05-11       Impact factor: 5.482

Review 4.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

5.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

Review 6.  Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Authors:  Lucas Minig; Cristina Zorrero; Pablo Padilla Iserte; Andres Poveda
Journal:  World J Methodol       Date:  2015-12-26

7.  Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.

Authors:  Ashley L Cole; Emma L Barber; Anagha Gogate; Arthur-Quan Tran; Stephanie B Wheeler
Journal:  Int J Gynecol Cancer       Date:  2018-07       Impact factor: 3.437

8.  Comparative effectiveness research in gynecologic oncology.

Authors:  Sonali Patankar; Ana I Tergas; Jason D Wright
Journal:  Cancer Treat Res       Date:  2015

Review 9.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

Review 10.  Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed?

Authors:  Keiichi Fujiwara; Akira Kurosaki; Kosei Hasegawa
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.